Standard Biotools (LAB) Cost of Revenue (2010 - 2026)

Standard Biotools (LAB) has 17 years of Cost of Revenue data on file, last reported at $9.8 million in Q1 2026.

• Quarterly Cost of Revenue rose 7.25% year-over-year to $9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.5 million (down 2.73% YoY) and the FY2025 annual result came in at $42.8 million, down 7.23% from the prior year.
• Cost of Revenue declined to $9.8 million in Q1 2026 per LAB's latest filing, from $12.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $21.4 million in Q1 2024 and bottomed at $1.9 million in Q1 2022.
• The 5-year median for Cost of Revenue is $12.8 million (2023), against an average of $12.6 million.
• The widest annual swing landed in 2023, when Cost of Revenue soared 565.87%; it then sank 57.04% in 2025.
• Tracing LAB's Cost of Revenue over 5 years: stood at $15.9 million in 2022, then declined by 6.45% to $14.8 million in 2023, then slipped by 9.51% to $13.4 million in 2024, then declined by 7.5% to $12.4 million in 2025, then retreated by 20.74% to $9.8 million in 2026.
• Per Business Quant, the three latest LAB Cost of Revenue figures stand at $9.8 million (Q1 2026), $12.4 million (Q4 2025), and $10.1 million (Q3 2025).

Peer Comparison